MissionIR News - VistaGen Therapeutics Announces Strategic Agreement With Cato BioVentures and Cato Research to Increase Its Drug Rescue Opportunities

Share Article

Company utilizes its versatile stem cell technology platform in expanded relationship with global contract research and development organization

By applying the power of human pluripotent stem cell technology, we believe VistaGen is transforming drug development.

MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCBB: VSTA). VistaGen Therapeutics is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of promising drug candidates that have been discontinued during preclinical development ("put on the shelf") due to heart or liver safety concerns.

In the company’s news yesterday, VistaGen Therapeutics announced it has expanded its long-term relationship with Cato BioVentures and Cato Research to include right-of-first-offer for potential drug rescue candidates.

The companies will join forces to identify, evaluate, rescue and develop once-promising new, small-molecule drug candidates discontinued in late-stage preclinical development by pharmaceutical developers due to heart or liver toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits.

Shawn Singh, VistaGen’s Chief Executive Officer, stated, “Over the past 25 years, Dr. Allen Cato and Lynda Sutton have established Cato Research as a highly successful CRO with unique and long-standing relationships within a broad and diverse network of pharmaceutical companies and regulatory agencies around the world. This new agreement is a logical extension of our long-term relationship with both Cato BioVentures and Cato Research. It tightly aligns our stem cell technology-based drug rescue interests with Cato’s CRO growth goals and venture investment objectives. We believe the market demand for effective late-stage preclinical candidates with safety data generated with human heart cells and/or liver cells is strong and increasing. This relationship is yet another key component in our drug rescue ecosystem.”

Going forward, when either Cato BioVentures or Cato Research first becomes aware of a new drug candidate meeting VistaGen’s drug rescue selection criteria, it will approach VistaGen with information about the candidate before any other organization. It is anticipated that the expanded relationship will provide VistaGen with potential drug rescue opportunities from within Cato’s broad CRO service and venture capital networks. If VistaGen rescues (generates a new chemical variant of) a drug rescue candidate presented by Cato Research or Cato BioVentures, VistaGen will discuss prospective CRO service opportunities for the new chemical entity with Cato Research before contacting any other CRO.

“By applying the power of human pluripotent stem cell technology, we believe VistaGen is transforming drug development. Its Human Clinical Trial in a Test Tube™ platform puts clinically relevant human heart and liver biology at the front end of the development process, long before human studies. We are pleased to join VistaGen’s efforts to identify and develop new drug candidates faster and less expensively through the use of its stem cell technology platform,” commented Allen Cato, M.D., Ph.D., co-founder and Chief Executive Officer of Cato Research.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

MissionIR Communications
Visit website